An Updated and Focused Review on Heterocyclic Inhibitors for SARS-CoV and SARS-CoV-2 3CLpro

被引:1
|
作者
Manaithiya, Ajay [1 ]
Alam, Ozair [1 ]
Mittal, Shruti [1 ]
Naim, Mohd. Javed [1 ]
Imran, Mohd [2 ]
Alshrari, Ahmed Subeh [3 ]
Sheikh, Aadil A. A. [1 ]
Khan, Imran A. A. [4 ]
机构
[1] Jamia Hamdard, Sch Pharmaceut Educ & Res, Med Chem & Mol Modelling Lab, Dept Pharmaceut Chem, New Delhi 110062, India
[2] Northern Border Univ, Fac Pharm, Dept Pharmaceut Chem, Rafha 91911, Saudi Arabia
[3] Northern Border Univ, Fac Appl Med Sci, Med Lab Technol, Ar Ar, Saudi Arabia
[4] Jamia Hamdard, Sch Chem & Life Sci, Dept Chem, New Delhi 110062, India
关键词
SARS-CoV; SARS-CoV-2; biological activity; structure-activity relationship; molecular docking; heterocyclic inhibitors; ACUTE RESPIRATORY SYNDROME; 3CL PROTEASE INHIBITORS; CORONAVIRUS DISEASE 2019; ANTIVIRAL ACTIVITY; BIOLOGICAL EVALUATION; ISATIN DERIVATIVES; COVID-19; INFECTION; VIRAL-RNA; IN-VITRO; IDENTIFICATION;
D O I
10.2174/1389557522666220511125102
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background SARS-CoV and SARS-CoV-2 are exceedingly contagious and typically result in major respiratory illnesses (acute respiratory syndrome). The public health is facing enormous challenges across all the nations due to these newly emerging pathogens. Reliable and systematic examination of SARS-CoV and COVID-19 will assist in identifying infectious persons accurately. Based on the biological, chemical, and genetic link of SARS CoV-2 towards SARS-CoV, the recurrence of different anti-SARS-CoV natural drug molecules may be beneficial in the advancement of anti-COVID-19 herbal drug molecules. Here in this review, we evaluated SAR research that has recently been published as well as molecular docking analysis of previously synthesised compounds that have been targeted against SARS-CoV and SARS-CoV-2, respectively. This investigation might assist scientists in creating novel and revolutionary molecules that could target SAR-CoV-2. Objectives The review highlights the heterocyclic inhibitors' ability to successfully inhibit SARS-CoV and SARS-CoV-2. The meticulously described structure-activity relationship of potential SARS-CoV and SARS-CoV-2 inhibiting compounds has been addressed in this review. Evidence Acquisition We conducted a thorough literature assessment employing electronic databases for scientific articles highlighting potential heterocyclic inhibitors for SARS-CoVand SARS-CoV-2, published from 2010 to 2021. We recovered 415 articles, but only 220 were involved and conversed in this manuscript. The article apprehended appropriate research considering three areas: 1) SAR activity, 2) Molecular docking, and 3) Biological activity and future prospects on SARS-CoV-2. Methods The potential compounds with decent inhibitory activity have been discussed and reviewed along with their inhibition potential, expressed in terms of IC50 value. Results Heterocyclic scaffolds reflect an extensive spectrum of therapeutic activity and might function as an initiating concept for the designing and discovery of potential inhibitors for SARS-CoV and SARS-CoV-2 treatment. Conclusion The points highlighted here may prove to be a vital tool for medicinal chemists working/investigating more potent and efficacious scaffolds in treating SARS-CoV and SARS-CoV-2.
引用
收藏
页码:576 / 632
页数:57
相关论文
共 50 条
  • [1] Profiling of Substrate Specificity of SARS-CoV 3CLpro
    Chuck, Chi-Pang
    Chong, Lin-Tat
    Chen, Chao
    Chow, Hak-Fun
    Wan, David Chi-Cheong
    Wong, Kam-Bo
    PLOS ONE, 2010, 5 (10):
  • [2] Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds
    Zhu, Jiajie
    Zhang, Haiyan
    Lin, Qinghong
    Lyu, Jingting
    Lu, Lu
    Chen, Hanxi
    Zhang, Xuning
    Zhang, Yanjun
    Chen, Keda
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 1067 - 1082
  • [3] Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors
    Paul, Abhik
    Sarkar, Arnab
    Saha, Sanjukta
    Maji, Avik
    Janah, Pritha
    Maity, Tapan Kumar
    BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 46
  • [4] SARS-CoV-2 3CLpro displays faster self-maturation in vitro than SARS-CoV 3CLpro due to faster C-terminal cleavage
    Kuo, Chih-Jung
    Liang, Po-Huang
    FEBS LETTERS, 2022, 596 (09) : 1214 - 1224
  • [5] Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV
    Panchal, Disha
    Kataria, Jeena
    Patel, Kamiya
    Crowe, Kaytlyn
    Pai, Varun
    Azizogli, Abdul-Rahman
    Kadian, Neil
    Sanyal, Sreya
    Roy, Abhishek
    Dodd-o, Joseph
    Acevedo-Jake, Amanda M.
    Kumar, Vivek A.
    ADVANCED THERAPEUTICS, 2021, 4 (10)
  • [6] Comparative protein structure network analysis on 3CLpro from SARS-CoV-1 and SARS-CoV-2
    Lata, Surabhi
    Akif, Mohd.
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2021, 89 (09) : 1216 - 1225
  • [7] Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition
    Ryu, Young Bae
    Jeong, Hyung Jae
    Kim, Jang Hoon
    Kim, Young Min
    Park, Ji-Young
    Kim, Doman
    Naguyen, Thi Thanh Hanh
    Park, Su-Jin
    Chang, Jong Sun
    Park, Ki Hun
    Rho, Mun-Chual
    Lee, Woo Song
    BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (22) : 7940 - 7947
  • [8] A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors
    Vankadara, Subramanyam
    Wong, Yun Xuan
    Liu, Boping
    See, Yi Yang
    Tan, Li Hong
    Tan, Qian Wen
    Wang, Gang
    Karuna, Ratna
    Guo, Xue
    Tan, Shu Ting
    Fong, Jia Yi
    Joy, Joma
    Chia, C. S. Brian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 48
  • [9] Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
    Kuang, Yi
    Ma, Xiaodong
    Shen, Wenjing
    Rao, Qingqing
    Yang, Shengxiang
    FUTURE SCIENCE OA, 2023, 9 (04):
  • [10] Exploring New Small Molecule Inhibitors for SARS-CoV-2 3CLpro: A Comprehensive Computational Study
    Hernandez-Hernandez, Jose Manuel
    Avila-Aviles, Rodolfo Daniel
    CHEMISTRYSELECT, 2024, 9 (37):